Headline News

 

FDA grants priority review to Padcev and Keytruda for muscle invasive bladder cancer

Posted on April 21, 2026

Blenrep approved in China for 2L+ relapsed or refractory multiple myeloma

Posted on April 21, 2026

Lilly’s oral GLP 1 Foundayo hits primary endpoint in landmark ACHIEVE 4 cardiovascular trial

Posted on April 21, 2026

Eli Lilly set to acquire Kelonia Therapeutics in $7 billion genomic medicine play

Posted on April 21, 2026

AbbVie presents compelling ovarian cancer data that could significantly expand ELAHERE’s market reach

Posted on April 14, 2026

Novo Nordisk secures EU regulatory approval to streamline Wegovy distribution, paving way for broader home delivery

Posted on April 14, 2026

Novo Nordisk partners with OpenAI to accelerate drug discovery

Posted on April 14, 2026

Revolution Medicines opens first line pancreatic cancer trial as Daraxonrasib programme expands

Posted on April 14, 2026

Neurocrine Biosciences set to acquires Soleno Therapeutics in $2.9 billion rare disease deal

Posted on April 14, 2026

Spyre Therapeutics showcases positive phase 2 data for SPY001 in ulcerative colitis, opening enrolment for combination cohorts

Posted on April 14, 2026

Daraxonrasib highlights overall survival benefit in patients with metastatic pancreatic cancer

Posted on April 14, 2026

Gilead moves to bolster cancer pipeline with €3 billion german biotech buyout

Posted on April 14, 2026

AstraZeneca’s Alexion unit set to showcase broad rare disease data at AAN 2026

Posted on April 14, 2026

Lilly’s Foundayo (new oral GLP-1 pill for weight loss) now available in the U.S.

Posted on April 14, 2026

INLEXZO received permanent billing code highlighting access for patients with certain bladder cancers

Posted on April 07, 2026